| Literature DB >> 30497614 |
Abstract
Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30497614 PMCID： PMC6589807 DOI： 10.1016/j.it.2018.10.009
Source DB: PubMed Journal: Trends Immunol ISSN： 1471-4906 Impact factor: 16.687